No Data
ch biotech ser (08037): The capital injection agreement has expired.
Ch biotech ser (08037) announced that on November 15, 2024, the prerequisites have not been met...
ch biotech ser (08037) showcased the updated clinical trial results of LY007 cell injection at the 2024 American Society of Hematology Annual Meeting.
ch biotech ser (08037) announced that its indirect non-wholly-owned subsidiary shanghai longyao biotechnology limited...
Announcement Selection | cspc pharma plans to repurchase up to 5 billion Hong Kong dollars of shares; Sun Insurance: Sunshine Life Insurance premium income from January to August is 66.384 billion yuan
China Railway Signal & Communication Corporation (03969.HK) won a total of approximately 2.9 billion yuan worth of projects from July to August; Tencent (00700.HK) spent 1.002 billion Hong Kong dollars on repurchasing 2.6 million shares on September 19; Alibaba-SW (09988.HK) spent 59.977 million US dollars on repurchasing 5.678 million shares on September 18.
Hong Kong stock announcement | Goldensolar plans to join hands with Juhua Energy and Longi Green Energy Technology to establish a joint venture company to produce HBC solar batteries.
Dingqiao Communication and China Soft International have signed a cooperation agreement to jointly start a new chapter of domestic cooperation...
Ch Biotech Ser (08037.HK) plans to cooperate with Jinshazhou Hospital of Guangzhou University of Traditional Chinese Medicine in the fields such as boron neutron capture therapy pharmaceuticals and medical instruments, referral cooperation, equity coopera
On September 19, 2024, Ch Biotech Ser (08037.HK) announced that on September 19, 2024, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd. ("Pengbo (Hainan)") (a wholly-owned subsidiary indirectly owned by the company) entered into a cooperation framework intention letter with Jinshazhou Hospital of Guangzhou University of Traditional Chinese Medicine ("the hospital"). The main areas of cooperation include boron neutron capture therapy (BNCT) treatment drugs and medical instruments, referral cooperation, equity cooperation, and indication expansion. The hospital is approved by the Guangzhou Health Commission and is a medical institution that integrates medical
CH BIOTECH SER: INTERIM REPORT 2024
No Data
No Data